Anti-Human CD3 x BCMA (Elranatamab) (C3270-1.0mg)

CD3 is an invariant antigen of the T cell TCR (T cell receptor)1. BCMA is a member of the tumor necrosis factor family of receptors that regulates B cell maturation, proliferation, and survival by activating p38/NF-κB and inducing upregulation of antiapoptotic proteins2. BCMA is highly expressed on multiple myeloma (MM) cells and is therefore a target of cancer immunotherapy. Anti-Human CD3 x BCMA bispecific antibodies target both B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells, inducing T-cell activation and cytotoxic activity against BCMA-expressing plasma cells. Elranatamab (RN613), a bispecific antibody targeting BCMA and CD3 on T-cells, has shown potent T-cell-mediated anti-myeloma activity by bringing T-cells close to myeloma cells. Elranatamab is distributed in the body, with higher concentrations in blood and lymphatic tissues. In laboratory settings, Elranatamab is used to study the efficacy of bispecific antibodies in targeting multiple myeloma and to develop therapeutic strategies for relapsed or refractory multiple myeloma3,4.